NeoGenomics (NASDAQ:NEO – Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, July 29th. Analysts expect the company to announce earnings of $0.00 per share for the quarter. NeoGenomics has set its FY 2024 guidance at 0.000-0.040 EPS.Parties interested in listening to the company’s conference call can do so using this link.
NeoGenomics (NASDAQ:NEO – Get Free Report) last issued its earnings results on Tuesday, April 30th. The medical research company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). NeoGenomics had a negative return on equity of 3.54% and a negative net margin of 13.79%. The firm had revenue of $156.24 million for the quarter, compared to analysts’ expectations of $149.82 million. On average, analysts expect NeoGenomics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NeoGenomics Price Performance
Shares of NEO stock opened at $14.88 on Friday. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.48 and a quick ratio of 7.22. The firm’s 50-day moving average is $13.93 and its two-hundred day moving average is $14.69. NeoGenomics has a 12 month low of $11.03 and a 12 month high of $21.22. The company has a market capitalization of $1.90 billion, a PE ratio of -22.55 and a beta of 1.19.
Wall Street Analyst Weigh In
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Recommended Stories
- Five stocks we like better than NeoGenomics
- Trading Stocks: RSI and Why it’s Useful
- Why Call Options Volume for These 2 Stocks Spiked Together
- Why Are These Companies Considered Blue Chips?
- MarketBeat Week in Review – 7/22 – 7/26
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.